Back to search

Article

The combination of fruquintinib, raltitrexed and S-1 as a third-line treatment for metastatic colorectal cancer: A case report

2022-07-06

Abstract excerpt

Effective late-line therapies for metastatic colorectal cancer (mCRC) are urgently needed. This case report presents a patient with mCRC who received third-line treatment with fruquintinib, raltitrexed and S-1. A 54-year-old male presenting with hematochezia was admitted to our hospital in June 2017 and underwent surgery for a tumor between the rectum and sigmoid colon. Postoperative pathology identified adenocarc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
80ed5ba6-0354-59a1-8a8b-81051464f918
DOI
10.21203/rs.3.rs-1821994/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The combination of fruquintinib, raltitrexed and S-1 as a third-line treatment for metastatic colorectal cancer: A case reportDOI 10.21203/rs.3.rs-1821994/v1
Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Semantic proximity
BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer-A Case Series Study Target Therapy of BRAF-Mutated mCRC.Semantic proximity
Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report.Semantic proximity
Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumabSemantic proximity
Oncological Outcomes of Patients with Peritoneal Metastasis–only Colorectal Cancer Treated with First-line Bevacizumab and FOLFIRI through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis–only, and Lung Metastasis–onlySemantic proximity
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.Semantic proximity
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.Semantic proximity
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation studySemantic proximity
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.Semantic proximity
Real-World Outcomes of First-line and Second-line Chemotherapy with Dabrafeniband Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single CenterSemantic proximity
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.Semantic proximity
Select a neighboring publication to make it the new centre.